Oxford, UK, 5 April 2012, Summit (AIM: SUMM), a UK drug discovery company, has been notified that Mr Glyn Edwards, Chief Executive Officer of Summit, purchased 400,000 Ordinary Shares of 1 pence each at a price of 3.49 pence per share on 4 April 2012.
Mr Edwards now holds a total of 800,000 shares representing 0.43 per percent of the issued share capital. This figure excludes the Placing Shares Mr Edwards has subscribed for under the Placing announced by the Company yesterday.
Pursuant to the Placing, the Directors have agreed to subscribe for such number of Placing Shares as follows:
Director Number of Placing Shares
Barry Price 400,000
Stephen Davies 500,000
Andrew Richards 200,000
Glyn Edwards 2,666,667
Richard Storer 200,000
For more information, please contact:
Summit
Glyn Edwards / Richard Pye
Tel: +44 (0)1235 443 939
Singer Capital Markets
(Nominated Adviser and Joint broker)
Shaun Dobson / Claes Spång
Tel: +44 (0)203 205 7500
Hybridan LLP
(Joint broker)
Claire Louise Noyce / Deepak Reddy
Tel: +44 (0)207 947 4350
Peckwater PR
(Financial public relations)
Tarquin Edwards
Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk
About Summit
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin™ technology platform for the discovery of new medicines and a portfolio of drug programme assets. Summit’s programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.
Further information is available at www.summitplc.com.
